Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Zynteglozynteglo.com · Low evidenceZYNTEGLO is an FDA-approved gene therapy for adult and pediatric patients with beta thalassemia who require regular blood transfusions. In clinical studies, approximately 89% of treated patients achieved transfusion independence with normal or near-normal hemoglobin levels.
Parse Score